Skip to content

Exploration of the Application of Dual-energy CT Quantitative Analysis of Hydroxyproline in Fibrotic Interstitial Lung Diseases

Exploration of the Application of Dual-energy Spectral CT Quantitative Analysis of Hydroxyproline in the Diagnosis of Fibrotic ILD

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600129002
Enrollment
Unknown
Registered
2026-07-29
Start date
2026-07-31
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Various subtypes of interstitial lung diseases

Interventions

Patients with interstitial lung disease(Experimental group):None
healthy individuals undergoing physical examination (Control group):None

Sponsors

First Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age > 18 years old; 2.Experimental group: Had undergone at least one dual-energy 256-slice Revolution CT GSI scan of the chest (examination method: performed chest scan using the American GE dual-energy 256-slice Revolution CT; scanning parameters: GSI mode, tube voltage 120 kv, automatic tube current (200-450 mA), slice thickness 0.625 mm, pitch 0.992, matrix 512×512. Scan range: supine position, from the apex of both lungs to the lung base. Scanning phase: inspiratory phase. ) and the CT indicated interstitial lung changes (refer to the 2025 ATS definition: non-weight-dependent bilateral lung parenchymal abnormalities on CT images, including ground-glass opacities, reticular shadows, abnormal lung volume, tractional bronchial dilation or honeycomb-like changes, and involving more than 5% of the lung area). 3.Control group: Chest CT indicated only scattered small nodules (the number of nodules was less than 10 and the diameter of each nodule was less than 5mm) or no obvious abnormal shadows were observed in the lung parenchyma. 4.Agree to use the chest CT images and clinical data for this study; 5.The subjects were informed and gave their consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1.Including severe pulmonary emphysema, lung malignancies, pulmonary consolidation, atelectasis, acute pulmonary infection, pneumoconiosis, and pulmonary tuberculosis, etc., all of which are serious diffuse lung disorders. 2.Pregnant and lactating women; 3.Poor quality of CT images or CT during exhalation phase; 4.Not signing the informed consent form;

Design outcomes

Primary

MeasureTime frame
The hydroxyproline density and lung volume measured by spectral CT;

Countries

China

Contacts

Public ContactZhang Jianqing

First Affiliated Hospital of Kunming Medical University

ydyyzjq@163.com+86 871 65324888

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026